Non-pharmacological treatment for attention deficit in adults with ADHD: the case of: Transcranial direct current stimulation( tDCS)

By Stefano Pallanti and Luana Salerno

Regardless off the well-documented efficacy of pharmacological treatment in reducing ADHD symptomatology, there are many reasons why most people with ADHD do not take stimulants. Among these, stigma and fear regarding potential side effects, poor clinical response or poor tolerability. Moreover, concerns about the risk for stimulant abuse and diversion can limit their prescription.

In the following randomized, double-blind, parallel, sham-controlled trial of 4 weeks’ home-based tDCS treatment in adults with a diagnosis of ADHD, results showed decreased inattention symptomatology after anodal stimulation compared to sham, but no significant effects on hyperactivity-impulsivity symptoms, depression, anxiety and executive functions. Only mild adverse events, such as skin redness and scalp burn have been reported, and a dropout rate of 14%, primarily due to restrictions to circulation due to COVID-19 pandemic.

The study is very interesting since it has several differences compared to previous tDCS studies, i.e., the high number of participants, the use of a home-based device that can be particularly useful for those patients who physically live in geographically remote areas or have physical disabilities, the high number of sessions (the highest number of sessions so far applied to adults with ADHD), the parallel design which excludes the potential carryover effect of tDCS of the crossover design.

It would be noted that the ADHD sample included in this study had no current moderate to severe symptoms of depression or anxiety, and this is rarely found in a clinical setting where psychiatric comorbidities are very frequent, therefore it would take more studies to confirm these findings. Furthermore, some patients were taking medication for depression and anxiety with a potential mild effect of inattention (such as bupropion and venlafaxine), and the higher number of dropouts in the active group compared to the sham group may have influenced the results reported.

Despite these limitations, in a context where there is a continuous search for effective non-pharmacological interventions, the possibility of a home-based tDCS treatment to reduce inattention in those individuals with ADHD who cannot take stimulants should be further explored.

Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial – PubMed (nih.gov):

Abstract

Importance:
Transcranial direct current stimulation (tDCS) may improve symptoms of inattention in adults with attention-deficit/hyperactivity disorder (ADHD). However, previous trials are characterized by small sample sizes, heterogeneous methodologies, and short treatment periods using clinic-based tDCS.

Objective:
To determine the efficacy and safety of home-based tDCS in treating inattention symptoms in adult patients with ADHD.

Design, setting, and participants:
Randomized, double-blind, parallel, sham-controlled clinical trial (tDCS for the Treatment of Inattention Symptoms in Adult Patients With ADHD [TUNED]), conducted from July 2019 through July 2021 in a single-center outpatient academic setting. Of 277 potential participants screened by phone, 150 were assessed for eligibility on site, and 64 were included. Participants were adults with ADHD, inattentive or combined subtype. Exclusion criteria included current stimulant drug treatment, current moderate to severe symptoms of depression or anxiety, diagnosis of bipolar disorder with a manic or depressive episode in the last year, diagnosis of schizophrenia or another psychotic disorder, and diagnosis of autism spectrum disorder; 55 of participants completed follow-up after 4 weeks.

Interventions:
Thirty-minute daily sessions of home-based tDCS for 4 weeks, 2 mA anodal-right and cathodal-left prefrontal stimulation with 35-cm2 carbon electrodes.

Main outcomes and measures:
Inattentive scores in the clinician-administered version of the Adult ADHD Self-report Scale version 1.1 (CASRS-I).

Results:
Included in this trial were 64 participants with ADHD (31 [48%] inattentive presentation and 33 [52%] combined presentation), with a mean (SD) age of 38.3 (9.6) years. Thirty participants (47%) were women and 34 (53%) were men. Fifty-five finished the trial. At week 4, the mean (SD) inattention score, as measured with CASRS-I, was 18.88 (5.79) in the active tDCS group and 23.63 (3.97) in the sham tDCS group. Linear mixed-effects models revealed a statistically significant treatment by time interaction for CASRS-I (βinteraction = -3.18; 95% CI, -4.60 to -1.75; P < .001), showing decreased symptoms of inattention in the active tDCS group over the 3 assessments compared to the sham tDCS group. Mild adverse events were more frequent in the active tDCS group, particularly skin redness, headache, and scalp burn.

Conclusions and relevance:
In this randomized clinical trial, daily treatment with a home-based tDCS device over 4 weeks improved attention in adult patients with ADHD who were not taking stimulant medication. Home-based tDCS could be a nonpharmacological alternative for patients with ADHD.

Trial registration:
ClinicalTrials.gov Identifier: NCT04003740.